Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 09:57:52 2026-01-15 am EST			5-day change	1st Jan Change
365.35 ^DKK	-3.41%		-0.74%	+13.02%

09:10am	Novo Nordisk Foundation Grants $856 Million to BioInnovation Institute to Boost Innovation in Denmark, Europe	MT
08:45am	Novo Nordisk Foundation Pledges Up to DKK5.5 Billion for Denmark's BioInnovation Institute	MT

Novo Nordisk steady amid Lilly Retatrutide risks

Eli Lilly’s Retatrutide posted standout efficacy but a higher discontinuation rate cooled the market reaction, while Novo Nordisk investors focus on Oral Wegovy and Amycretin as the Obesity landscape pivots toward both injectable and oral weight loss options into 2026.

Published on 12/12/2025 at 11:14 am EST - Modified on 12/12/2025 at 06:00 am EST

Alphavalue

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Novo Nordisk A/S

09:10am	Novo Nordisk Foundation Grants $856 Million to BioInnovation Institute to Boost Innovation in Denmark, Europe	MT
08:45am	Novo Nordisk Foundation Pledges Up to DKK5.5 Billion for Denmark's BioInnovation Institute	MT
08:24am	NOVO NORDISK : Barclays reiterates its Neutral rating	ZD
04:51am	NOVO NORDISK : UBS reiterates its Neutral rating	ZD
03:06am	AbbVie: stepping up obesity treatments with an alternative approach to GLP-1
02:57am	PriorNilsson Sverige Aktiv Rose 2.14 Percent in December – Alfa Laval Contributed Most	FW
02:43am	NOVO NORDISK : Buy rating from JP Morgan	ZD
02:39am	UBS Raises Target Price for Novo Nordisk to 390 Danish Kroner (from 295), Reiterates Neutral Rating	FW
Jan. 14	Sector Update: Health Care Stocks Higher Late Afternoon	MT
Jan. 14	Sector Update: Health Care	MT
Jan. 14	Structure expects pills to capture up to 50% of GLP-1 obesity market by 2030	RE
Jan. 14	Novo Nordisk to Keep Pursuing Deals to Expand Obesity Portfolio, CEO Says	MT
Jan. 14	AbbVie plans to build out its presence in obesity market	RE
Jan. 14	Novo Nordisk Is Looking for Obesity Deals, Bloomberg Says, Citing CEO	DJ
Jan. 14	Boring No More
Jan. 14	Novo Nordisk Ready for Major Acquisitions in Obesity Sector, Says CEO - BN	FW
Jan. 14	Novo Nordisk expects a temporary international setback amid intensifying competition
Jan. 14	White House interventionism rattles Wall Street
Jan. 13	Denmark's Novo Nordisk Eyes Further Deals to Grow Obesity Portfolio	MT
Jan. 13	Novo CEO Sees Strong Demand for Wegovy Obesity Pill	MT
Jan. 13	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Jan. 13	Novo Nordisk flags near-term headwinds in international operations	RE
Jan. 13	Novo Nordisk A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 09:45 AM
Jan. 13	Novo Nordisk flags near-term headwinds in international markets	RE
Jan. 13	Sector Update: Health Care Stocks Decline Tuesday Afternoon	MT

Chart Novo Nordisk A/S

Duration

Period

NOVO B: Dynamic Chart

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

78,554

Sector

Pharmaceuticals

Calendar

Feb. 04 - Q4 2025 Earnings Release

More about the company